Sequential Low-Dose Rate Half-Body Irradiation and Chemotherapy for the Treatment of Canine Multicentric Lymphoma

• Published in: Journal of veterinary internal medicine Vol. 23; no. 5; pp. 1064 - 1070
• Main Authors: Lurie, D.M, Gordon, I.K, Theon, A.P, Rodriguez, C.O, Suter, S.E, Kent, M.S
• Format: Journal Article
• Language: English
• Published: Malden, USA Blackwell Publishing Inc 01.09.2009
• Subjects: Animals; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; chemotherapy; combination drug therapy; Combination therapy; Combined Modality Therapy; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Dog Diseases - drug therapy; Dog Diseases - pathology; Dog Diseases - radiotherapy; Dogs; Dose-Response Relationship, Radiation; Doxorubicin - administration & dosage; Doxorubicin - adverse effects; Efficacy; Female; Hematocrit - veterinary; Hemibody Irradiation - methods; Hemibody Irradiation - veterinary; Immunophenotyping - veterinary; Kaplan-Meier Estimate; lymphoma; Lymphoma - drug therapy; Lymphoma - pathology; Lymphoma - radiotherapy; Lymphoma - veterinary; Male; Prednisone - administration & dosage; Prednisone - adverse effects; radiotherapy; Retrospective Studies; Vincristine - administration & dosage; Vincristine - adverse effects
• ISSN: 0891-6640; 1939-1676
• DOI: 10.1111/j.1939-1676.2009.0353.x

Background: Sequential half‐body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2‐week interradiation interval is possible in most dogs receiving low‐dose rate irradiation (LDRI) protocols at 6 Gy dose levels. Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)‐based chemotherapy protocol is effective for the treatment of lymphoma in dogs. Animals: Thirty‐eight client‐owned animals diagnosed with multicentric lymphoma. Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy. Results: The median 1st remission was 410 days (95% confidence interval [CI] 241–803 days). The 1‐, 2‐, and 3‐year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334–1,223 days). The 1‐, 2‐, and 3‐year survival rates were 66, 47, and 44%. Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2‐week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.